ADAPTIMMUNE THERAPEUTICS PLC
Income Statement
| Line Item | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $13.7M | $7.3M | $3.2M | $40.9M | $128.2M | $5.7M | $231.0K | $7.3M |
| Cost of Revenue | $2.5M | $879.0K | — | — | — | — | — | — |
| Gross Profit | $11.2M | $6.4M | — | — | — | — | — | — |
| Gross Margin | 81.7% | 87.9% | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $23.0M | $28.9M | $39.1M | $34.3M | $40.4M | $35.2M | $33.2M | $37.8M |
| SG&A Expense | $18.5M | $23.3M | $27.2M | $21.3M | $19.1M | $19.7M | $16.9M | $16.2M |
| Operating Income | $-30.3M | $-45.7M | $-73.5M | $-14.7M | $68.7M | $-49.3M | $-49.9M | $-46.6M |
| Operating Margin | -221.5% | -627.8% | -2,281.8% | -35.9% | 53.6% | -867.6% | -21,582.7% | -637.1% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $-29.7M | $-47.0M | $-72.5M | $-16.8M | $70.0M | $-48.0M | $-48.6M | $-44.9M |
| Income Tax Expense | $612.0K | $575.0K | $1.7M | $831.0K | $526.0K | $526.0K | $-656.0K | $687.0K |
| Net Income | $-30.3M | $-47.6M | $-74.2M | $-17.6M | $69.5M | $-48.5M | $-47.9M | $-45.6M |
| Net Margin | -221.8% | -653.2% | -2,303.4% | -43.1% | 54.2% | -854.2% | -20,743.3% | -623.0% |
| EPS (Basic) | $-0.02 | $-0.03 | $-0.06 | $-0.01 | $0.05 | $-0.03 | $-0.04 | $-0.03 |
| EPS (Diluted) | $-0.02 | $-0.03 | $-0.05 | $-0.01 | $0.04 | $-0.03 | $-0.04 | $-0.03 |
| Shares Outstanding (Basic) | 1.58B | 1.54B | 1.51B | 1.53B | 1.53B | 1.45B | 1.21B | 1.36B |
| Shares Outstanding (Diluted) | 1.58B | 1.54B | 1.51B | 1.53B | 1.56B | 1.45B | 1.21B | 1.36B |
| Dividends Per Share | — | — | — | — | — | — | — | — |